One hundred twenty-two patients were randomly assigned to three groups of treatment (A, B, and C), with (1) ranitidine (300 mg q.d. for 6 weeks), (2) ranitidine (300 mg q.d. for 6 weeks) with amoxicillin (500 mg t.i.d.) and metronidazole (500 mg b.i.d.) for the first 12 days, or (3) colloidal bismuth subcitrate (120 mg q.i.d. for 6 weeks) with amoxicillin and metronidazole (at same dosages as in the latter group). Six weeks after the beginning of treatment, an endoscopy showed that ulcers had healed in 49 of 52 patients (94.2%) from whom Helicobacter pylori had been eradicated and in 59 of 70 patients (84.3%) from whom it had not (NS). The rates of H. pylori eradication in groups A, B, and C were zero, 47.5%, and 86.8%, respectively. At 6, 12, and 18 months, an endoscopy was repeated for monitoring ulcer recurrence and H. pylori status. Reinfection rates at 6 months were 42.1% and 15.1% in groups B and C, respectively (P õ .05). At 18 months, ulcers recurred in 82.9% (63) of 76 patients with noneradicated H. pylori infection, vs. 5.7% (2) of 35 patients without H. pylori infection (P õ .001). We conclude that colloidal bismuth subcitrate is more effective for eradication of H. pylori than ranitidine when given with amoxicillin plus metronidazole for the treatment of duodenal ulcer, as both early reinfection and ulcer recurrence are diminished.
Eradication of Helicobacter pylori modifies the natural his-
The problem for patients with duodenal ulcer nowadays is not the healing of the ulcer but the recurrence. Most peptic tory of peptic ulcer disease. In 1994 the National Institutes of Health conference recommended a 2-week bismuth-based triulcers heal within 1 -2 months of treatment with either H 2 -receptor antagonists or omeprazole at standard doses. It has ple-drug therapy, which eradicates the infection in 80% -90% of patients infected with H. pylori susceptible to metronidazole, been noted that ú70% -85% of patients have a recurrence in the first year after finishing conventional treatment for the ulcer as the first-line treatment for patients with peptic ulcer [4] . This regimen is complex, leading to poor compliance, which, and that nine of 10 such patients have symptoms. The maintenance of antisecretory treatment for months or years, depending together with antimicrobial resistance to nitroimidazoles (a major factor), is the usual cause of treatment failure [5] . Published on the activity of ulcer disease, has been recommended for many patients, but the cumulative rate of recurrence in a year data show a clear benefit in terms of a decrease in the duodenal and gastric ulcer recurrence rate when H. pylori is eradicated. is high [1] . Previous studies [2, 3] showed that the ulcer-healing rate following 2 weeks of bismuth treatment is 35% and after Eradication can reduce the recurrence rate from 80% to 20% at the 1-year follow-up [6 -9] , and this reduction extends to at 4 weeks is 84% -90%; only after 8 weeks does it reach 97% -100%. least 7 years after treatment [10] . The primary objective of our study was to compare the efficacy of ranitidine vs. colloidal bismuth subcitrate in combined treatment with amoxicillin and metronidazole in the erad- 
Patients
Informed consent was obtained from patients, and approval for the study protocol was granted by the Hospital Universitario de la Princesa Ethical
We selected 122 patients from a group of 307 included in Committee. a concurrent ecological study, which evaluated the prevalence copy (Olympus JF 1T20, Medical Europe, Barcelona) and preof duodenal ulcer healing, all three groups of patients were included in an 18-month prospective longitudinal cohort study sented with upper digestive tract symptoms. Criteria for exclusion from the study were recent digestive bleeding, coaguof the natural evolution of the disease and of the rate of ulcer recurrence in relation to H. pylori infection. At 6, 12, and 18 lation disorders, intake of antiulcer treatment (except antacids) in the preceding month, previous abdominal surgery, or maligmonths after the initial diagnosis, an endoscopy was performed to observe the gastroduodenal mucosa and to obtain biopsy nant lesions. Patients treated with antibiotics or nonsteroidal antiinflammatory drugs (NSAIDs) and corticosteroids before specimens for histologic examination and culture for H. pylori. Reversion to a positive H. pylori status indicated reinfection. the endoscopy were not excluded from the ecological study. In each case, it was noted whether the patient had a daily smoking habit.
Definition of Endpoints
Of all the patients with duodenal ulcers, 122 were enrolled in the trial. Conditions for inclusion in the study were as folEradication was defined as absence of the organism at reevallows: active duodenal ulcer and H. pylori infection; age of uation 4 weeks after the end of antibiotic treatment. Eradication 18 -65 years; a signed informed consent form; acceptance of was the clinically important endpoint of the trial. Clinical adthe conditions of the study and the prescribed revisions; no verse effects were recorded and evaluated for severity, outlong-term use of drugs (such as NSAIDs or corticosteroids) come, and relationship to the drugs used. Definition of ulcer due to other diseases; no antibiotic use in the preceding 4 recurrence required an endoscopic reevaluation, which was proweeks; no contraindication for endoscopy and/or biopsy; no posed to patients who presented with digestive symptoms lastprevious allergy to penicillin and derivates; and no participation ing ú1 week. If recurrence of the ulcer was confirmed, rein other therapeutic trials.
treatment was proposed. , direct histologic ex-Ç40 individuals to optimize the statistical analysis. The treatamination (hematoxylin/eosin, Giemsa, and Warthin-Starry silment assignments were determined by a list of random numbers ver staining), and examination with gram or acridine orange generated by computer. Patients were monitored for 18 months stains. Biopsy specimens were taken from the antrum (1 for for ulcer recurrence and status of H. pylori infection.
culture, 1 for a urease test, and 2 for histologic examination). Group A (44 patients) received ranitidine (Zantac; Glaxo, Both histologic and microbiological studies were done without Madrid) at a dosage of 300 mg q.d., given 1 hour after dinner knowledge of either the identity of the patient or the treatment for 6 weeks. This group was considered to be the control group, received. as the other two received treatment with the intention to eradiLesions of gastric mucosa were graded according to the cate H. pylori infection. Group B (40 patients) received ranitidmethods of Kekki et al. [11] for the classification of gastritis. ine (300 mg q.d., also given 1 hour after dinner for 6 weeks)
The culture medium used was agar supplemented with 5% plus amoxicillin (Clamoxyl; SmithKline Beecham, Madrid) at lysed horse blood and selective Skirrow supplement, and cula dosage of 500 mg t.i.d. and metronidazole (Flagyl; Rhonetures were incubated for 5 -7 days in microaerophilic condiPoulenc Rorer, Madrid) at a dosage of 500 mg b.i.d.; the latter tions. The bacterium was identified by gram staining and biotwo were given before meals for the first 12 days. Group C (38 chemical activity tests for urease, catalase, and oxidase. patients) received colloidal bismuth subcitrate (Gastrodenol; Cantabria Laboratories, Santander, Spain) at a dosage of 120 mg q.i.d., given before meals for 6 weeks, plus amoxicillin
Statistical Analysis
and metronidazole, administered as in group B. A 12-day duration of antibiotic treatment was considered most practical beContinuous data, presented as mean { SE, were compared by Student's t-test. Proportional data were compared by x 2 , cause of the packaging of the drugs in Spain.
In the 6th week a second endoscopy was done to confirm with Yates' correction and Fisher's exact test used when necessary. All tests performed were two-tailed. A P value of õ.05 healing. If the duodenal ulcer was not healed, treatment (with ranitidine or colloidal bismuth subcitrate) was maintained for was considered significant. Statistical calculations were performed with the statistical software package RSigma 2.0 (Horus 2 more weeks and a third endoscopy was performed afterward. After the clinical trial, and following endoscopic confirmation Hardware). The average incidence of side effects was 11.5% (14 of 122).
Follow-Up
A case of dizziness occurred in group A (2.3%; 1 of 44) in association with ranitidine. Six group B patients (15%; 6 of During follow-up 11 patients were excluded who did not 40) had side effects: diarrhea (3), abdominal and epigastric present for the prescribed endoscopy; spontaneously took antipain with nausea (2), and skin rash that disappeared at the end ulcer treatment because of digestive symptoms; had acute myoof the treatment with antibiotics (1). Seven patients in group cardial infarction; moved to another city; had recurrence of C (18.4%; 7 of 38) had side effects: epigastric disturbances, ulcers with digestive bleeding; underwent urgent gynecologic nausea, and cephalgia (3); moderate diarrhea (2); intense consurgery that required antibiotic therapy for a long period; or stipation with abdominal pain and mouth dryness (1); and glosbecame pregnant. These withdrawals are summarized as folsitis and candidal vulvovaginitis (1) . No statistical difference lows: group A, 2 patients after the 9th month and 3 patients in side effects was found between the groups taking antibiotics after the 15th; group B, 1 patient after the 9th month and 1 (P Å .68). None of the patients' symptoms were severe enough after the 15th; and group C, 1 patient after the 3rd month, 1 to necessitate withdrawal from the study.
after the 9th, and 2 after the 15th.
Ulcer Healing Eradication of H. pylori
In the 6th week after the beginning of treatment, healing of ulcers was confirmed in 80.3% of the patients (108 of 122).
There were no cases of eradication of H. pylori in the control group (group A). H. pylori status and reinfection rates during Treatment with ranitidine or colloidal bismuth subcitrate was prolonged for 2 more weeks for the 14 patients not healed, follow-up are shown in tables 2 and 3, respectively. In group B, treatment with ranitidine and the two antibiotics eradicated and in the 8th week another endoscopy was performed. This confirmed the healing of ulcers in 117 patients (95.9%) (6 vs.
H. pylori infection in 19 of 40 patients (47.5%). In group C, colloidal bismuth subcitrate achieved eradication in 33 of 38 8 weeks, NS; P Å .055). The five unhealed patients continued treatment for 2 more weeks, and healing was checked again in patients (86.8%). At 18 months of follow-up, the eradication rate was 23.6% (9 of 38 patients) in group B and 76.4% (26 the 10th week.
The rates of duodenal ulcer healing in the different treatment of 34 patients) in group C. Both differences in eradication were statistically significant (P õ .001). Reinfection rates at 6 groups at weeks 6 and 8 are shown in table 1. The rates were similar in all three groups at 6 weeks (86%, 90%, and 89%) months were 42.1% (8 of 19) and 15.1% (5 of 33) in groups Table 1 . Characteristics of patients in treatment groups A, B, and C and the duodenal ulcer healing rates with the three regimens at 6 and 8 weeks after treatment began. 4 . The groups were compared at 6, 12, and from whom it was eradicated. In duodenal ulcer recurrences, 18 months. Group A had the greatest rate of duodenal ulcer the risk attributable to H. pylori infection in cases of noneradirecurrence: 36.4%, 71%, and 87.2%, respectively, at 6, 12, and cation is 77% (95% CI, 0.71 -0.83). This figure may be consid-18 months. In group B the respective rates were 17.5%, 41%, ered the proportion by which ulcer recurrence would be reduced and 63.2%. The best results were achieved in group C, with if H. pylori infection were eradicated. duodenal ulcer recurrence rates of 13.5%, 19.4%, and 20.6%, respectively. The differences among the three groups were statistically significant: x 2 Å 6.9 (P õ .05, 2 df) at 6 months, Discussion x 2 Å 21.5 (P õ .001, 2 df) at 12 months, and x 2 Å 33.6 (P õ .001, 2 df) at 18 months.
Eradication of H. pylori modifies the natural history of peptic To reduce bias, we also analyzed the results with data from ulcer disease. Triple-drug therapy with bismuth plus metronidathe 11 patients lost during follow-up by counting patients in zole and amoxicillin achieved eradication in 73.1%, with no groups A and B as having no recurrences during follow-up and significant number of withdrawals despite a greater number of the patients lost in group C as all having recurrences. We thus side effects [12, 13] . The highest eradication rates (up to 94%) obtained a significant value of x 2 Å 19.6 (P õ .001, 2 df) and have been achieved with triple-drug therapy that includes metrates of ulcer recurrence of 77.3% in group A, 60% in group ronidazole, tetracycline, and bismuth salts given for 4 weeks. B, and 28.9% in group C at 18 months of follow-up.
In the search for the ideal anti-H. pylori treatment regimen, The evolution of ulcer recurrence was analyzed to ascertain combinations of amoxicillin and metronidazole with either the influence of H. pylori infection and its possible implication omeprazole or ranitidine have also been studied. in the more frequent rate of ulcer recurrence in groups A and A 2-week regimen of omeprazole, amoxicillin, and metronidazole achieved eradication in 96.4% of 55 patients infected with metronidazole-susceptible H. pylori and in 75% of 72 Table 3 . Rates of reinfection with Helicobacter pylori at 6, 12, and patients infected with metronidazole-resistant organisms [14] .
18 months after treatment began.
Hentschel et al. achieved similar results using ranitidine, amoxicillin, and metronidazole [15] . In our study, therapy with rani- The success rate of any H. pylori eradication regimen containing metronidazole is critically dependent on the frequency . We did not evaluate resistance in our patients, but it is possible that zero to 30% of therapy failures in groups B and by use of short-term antibiotic therapy instead of long-term therapy with H 2 -receptor antagonists. Using four routine tech-C were due to metronidazole resistance.
Side effects occur in approximately one-third of patients niques for diagnosis, Xia et al.
[26] reported a recrudescence rate of 14.3% in patients treated with triple-drug therapy includtaking triple-drug therapy, and 4% -17% of patients discontinue therapy because of side effects. Side effects described in ing amoxicillin and of 47.1% in patients treated with colloidal bismuth subcitrate alone; this raises questions regarding the previous studies include nausea/vomiting, diarrhea, rash, and pseudomembranous colitis [9] . In our trial, side effects of tripleadequate duration of testing for H. pylori eradication.
A study of 190 patients [27] after eradication of H. pylori drug therapy were moderate and occurred at a rate similar to that in other studies (18.4%), but none of the patients with side found that the risk of ulcer recurrence was 1% during each of the first 2 years of follow-up and zero during the 3rd and 4th effects withdrew from therapy.
Eradication of H. pylori can accelerate healing of duodenal years. Many investigators that have not segregated the first year from subsequent years of follow-up report unusually high peptic ulcer [15, 19 -21] . Five of the patients in our study needed therapy for 10 weeks to heal the ulcers, which were reinfection rates in the first 12 months, with dramatically reduced reinfection subsequently [28, 29] . We found reinfection considered refractory. Smoking and persistence of H. pylori can play a role when ulcers heal slowly [22, 23] . In the 6th rates at 6 months of 42.1% and 15.1%, respectively, with ranitidine and colloidal bismuth subcitrate. This significant differweek, duodenal ulcer healing was achieved in 94.2% of patients from whom H. pylori had been eradicated, vs. 84.3% of patients ence was not confirmed in the second or third semesters of follow-up, so early reinfection or late recrudescence exists. in whom it persisted. The difference is not significant probably because of the small samples.
It has been pointed out that many trials using colloidal bismuth subcitrate have high recrudescence rates. The hypothesis Reduced ulcer recurrence rates have been reported with use of regimens of antibiotics or bismuth salts that do not modify would be that colloidal bismuth subcitrate may have unusual bacteriologic effects, resulting in slow repopulation of the acid secretion but can eradicate H. pylori [8, 9] . In our study, the rates of ulcer recurrence at 18 months in group A (ranitistomach by H. pylori after cessation of therapy [26] . The multiple antral and corporal biopsy specimens used in our study dine) and group B (ranitidine plus amoxicillin and metronidazole) were 87.2% and 63.2%, respectively (P õ .05). The should have ensured high sensitivity, so the sample error should be small. Staining with Giemsa and Warthin-Starry silver stains difference between the groups (24%) is explained only by the action of the antibiotics on H. pylori, since the percentages of probably enhances the ability to detect H. pylori in the gastric mucosa. eradication in groups A and B were zero and 26.3%, respectively. In group C (colloidal bismuth subcitrate plus amoxicillin Our conclusions are as follows. (1) The eradication rate with the regimen of ranitidine plus amoxicillin and metronidazole and metronidazole) the most important reduction of ulcer recurrence was achieved, as only seven of 34 patients (20.6%) had was 47.5%, and that with the regimen of colloidal bismuth subcitrate plus amoxicillin and metronidazole was 86.8% a recurrence in 18 months. The rate of H. pylori eradication was best in this group (76.4%).
(P õ .001). (2) The reinfection rate at 6 months was higher with use of ranitidine than with colloidal bismuth subcitrate, When we considered data from the patients who withdrew as good results, we still obtained significant figures. The differalthough there was no difference in later reinfection rates between the two. (3) No significant differences were found in ences between results in group B and C were probably due to the use of bismuth salts, which have a double effect, in that duodenal ulcer healing rates at 6 weeks among patients from whom H. pylori was or was not eradicated. (4) The duodenal they are protective to the mucosa and bactericidal to H. pylori, although the latter property seems to be the principal one [10, ulcer recurrence rate is significantly lower with use of colloidal bismuth subcitrate than with ranitidine when given with amoxi-24, 25].
Our results at the end of the 18 months of follow-up show cillin and metronidazole, because the regimen better eradicates H. pylori. that patients in whom H. pylori infection was not eradicated had 82.9% of ulcer recurrences, vs. the 5.7% in patients without
